High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

Item

http://www.wikidata.org/entity/Q33416028

Q33416028

about

First line vs delayed transplantation in myeloma: Certainties and controversies Treatment of relapsed and refractory multiple myeloma Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce European perspective on multiple myeloma treatment strategies in 2014 Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial The Diagnosis and Treatment of Multiple Myeloma Managing multiple myeloma in elderly patients.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Design Advances in Particulate Systems for Biomedical Applications.Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.In vivo imaging to monitor differentiation and therapeutic effects of transplanted mesenchymal stem cells in myocardial infarction.Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): stu [Multiple myeloma : What has been confirmed in therapy?]Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study.Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation

P2860

Q26745957-F73DA63E-3541-4C50-AA41-09A6DD1FA9FC Q26749180-1FD486FE-B032-4968-9472-8718E0577C12 Q26771331-283BBF8C-941D-48CE-A8E3-13D602218622 Q26782868-66FCB0DF-2D59-46AF-845E-B69A3B47F7D4 Q27005966-3D13E29B-1482-4A37-94FF-D62A789063AF Q35999062-74185FDD-D45E-4353-AF23-9CFBA04E07B1 Q36138646-192B669C-5F8E-49FC-8D35-6EDDCE4D8B28 Q37150733-4850056F-5D2F-4D4E-AB9B-6559956B53A6 Q38605484-4AD5AE72-62E5-42B0-970E-8C685DC7CA5A Q38688055-0BD3A75D-ABE3-4080-AA99-B9FA2B6C3FFF Q38837339-33AFDB9A-C6D4-4AA9-A592-D6FA450F0A3E Q38859426-2FEC129E-8796-461D-9C9D-1224EA64E5F3 Q38873026-002DF2BD-32B2-459D-8F80-DCA5A3B879C4 Q38895415-A140A8F3-7D54-4E18-8703-E7F69F16E8FA Q38970597-ABE2A177-FEDA-48B2-A3EA-E55E9D8F61D6 Q39177792-6DCB80A4-7A8A-43B5-BBFC-B5FC31DA5240 Q39369772-4516451F-854F-454B-A6B4-83577ED8DF54 Q39379927-E8CC3D2C-4BEB-428C-9098-3FCCA71AB949 Q40121580-379F9C6D-A05E-4AEB-85CC-48662F5AEB6D Q40827148-0A08A288-9BAF-4D80-8886-E7D8BBFB91CC Q47283493-07E77D90-CCD0-4F81-ADFF-42ED489589D1 Q47587127-76ACA998-1868-404E-858D-93572FD44408 Q48130246-FEA92A3C-968B-4689-8E72-3C24CF637DB9 Q48139344-9877A6B5-90A8-4650-B800-A8AE32418D17 Q48337454-9A7640D7-469F-42C1-B80D-4DC0002AE82E Q49375952-3FC50916-1DD9-49C1-8C6B-67DE07F8BBDD Q51358936-9DD2DC8E-C9EB-48AF-AF05-2818C4A1CD98 Q51411892-5824176B-B514-434F-A53F-F51EFE38D847 Q52817414-0800A824-4DE5-49B2-BA2F-44B64D628A75 Q52836468-988C13CD-FA3D-4BE5-AB6D-C68B36E8DD21 Q52875785-76F972CB-760C-499C-8B20-3C7E6EB716F8 Q53544915-5B8A4764-1F6C-4B9B-B55C-B33E7B46A8F3 Q53838482-EC048E97-0AB9-4787-A36B-E162EE8E1838 Q53922357-13BD5F68-87A5-4838-AAC0-9F5483403D57 Q57903940-CA221449-465E-4EB7-B513-06E9426813CC

P2860

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

Item

http://www.wikidata.org/entity/Q33416028

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu